Table 2. Summary prevalence ratios for meta-analysis of changes in nonvaccine high-risk HPV types among girls and women, by age group*.
| Population age group, y, and HPVtype | No. studies† | Heterogeneity |
Prevalence ratio (95% CI) | |
|---|---|---|---|---|
| I2, % | p value | |||
| ≤19 | ||||
| HPV types in nonavalent vaccine | 8 | |||
| HPV31 | 6.4 | 0.381 | 0.73 (0.58–0.91) | |
| HPV33 | 0 | 0.471 | 1.04 (0.78–1.38) | |
| HPV45 | 5.5 | 0.387 | 0.96 (0.75–1.23) | |
| HPV52 | 24.0 | 0.238 | 1.34 (1.13–1.59) | |
| HPV58 | 0 | 0.727 | 1.01 (0.80–1.26) | |
| Other high-risk HPV types | 8 | |||
| HPV35 | 25.1 | 0.229 | – | |
| HPV39 | 0 | 0.984 | 1.27 (1.05–1.54) | |
| HPV51 | 43.6 | 0.088 | – | |
| HPV56 | 74.3 | <0.001 | – | |
| HPV59 | 66.8 | 0.004 | – | |
| HPV68 | 0 | 0.690 | 1.26 (0.88–1.81) | |
| Other possibly high-risk HPV types | 6 | |||
| HPV26 | 0 | 0.478 | 1.63 (0.84–3.16) | |
| HPV53 | 3.6 | 0.394 | 1.51 (1.10–2.06) | |
| HPV70 | 23.6 | 0.257 | 1.34 (0.75–2.39) | |
| HPV73 | 0 | 0.961 | 1.36 (1.03–1.80) | |
| HPV82 |
|
49.0 |
0.081 |
– |
| 20–24 | ||||
| HPV types in nonavalent vaccine | 8 | |||
| HPV31 | 28.8 | 0.198 | – | |
| HPV33 | 50.9 | 0.047 | – | |
| HPV45 | 64.3 | 0.007 | – | |
| HPV52 | 31.0 | 0.180 | – | |
| HPV58 | 0 | 0.806 | 1.14 (0.99–1.31) | |
| Other high-risk HPV types | 8 | |||
| HPV35 | 7.9 | 0.369 | 1.07 (0.85–1.34) | |
| HPV39 | 0 | 0.522 | 1.13 (1.00–1.28) | |
| HPV51 | 49.8 | 0.052 | – | |
| HPV56 | 82.6 | <0.001 | – | |
| HPV59 | 63.6 | 0.007 | – | |
| HPV68 | 35.6 | 0.145 | – | |
| Other possibly high-risk HPV types | 6 | |||
| HPV26 | 44.3 | 0.110 | – | |
| HPV53 | 30.8 | 0.204 | – | |
| HPV70 | 25.1 | 0.246 | – | |
| HPV73 | 59.2 | 0.032 | – | |
| HPV82 | 38.3 | 0.151 | – | |
*HPV, human papillomavirus; –, prevalence ratio not calculated because of heterogeneity of data. †Number of studies was the same for all HPV types within each category.